Abstract
Successful vendor–sponsor relationships, such as those between a contract research organization (CRO) and pharmaceutical company, assure and accelerate regulatory success for new products. Often, however, this relationship fails, which delays approval and, in turn, costs the pharmaceutical company money by shortening the market time of the product. Demetrius Carter, MBA, PMP, RAC-US, shared insight on this relationship at the AMWA Carolinas 2021 Spring Conference by providing methods of assuring and accelerating regulatory success for pharmaceutical companies, reasons that CRO–pharmaceutical company relationships fail, successful mitigation strategies, case studies illustrating failed relationships, and, finally, techniques to strengthen and transform the CRO–pharmaceutical company relationship into a strategic partnership.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
